Kisumu, Kenya, 16 April 2020 – a leading Africa provider of vaccine, drug, and device clinical trial services and solutions to the pharmaceutical, biotechnology, and medical device industries, today announced the activation of emergency operational response for COVID-19 – a regional operational resource to fast-track sponsored clinical trials of vaccines and therapeutics to help limit the course of COVID-19.
During the 2014 unprecedented Ebola virus outbreak in West Africa and 2018 in Central Africa, ACE Research together with partners was involved in the planning and execution of several activities and emergency public health responses. “Working together with MOH and partners, we strengthened clinical trial capacity and provided resources to sites in the affected regions that were intended to jumpstart research efforts in emergency public health situations” commented Dr. Amos Ndhere, Chief Medical Officer. “We must take this chance to leverage current investments and resources beyond Ebola virus disease to COVID-19”.
“ACE Research is deeply committed to driving COVID-19 vaccine development and we are working tirelessly to mobilize our regional resources throughout Africa to provide support to customers planning to replicate Ebolavirus successes and fast track evaluation of therapeutics
and vaccines in Sub-Saharan Africa.” Commented Jacob Apollo, CEO.
Since 2014 ACE Research has created a wide African footprint of experts and vaccine development resources to address emerging pathogens and biothreats research. Working with partners during Ebola outbreaks, we strengthened laboratory and cold chain infrastructure, coordinated central mechanisms that provided timely reviews of studies, ethical and regulatory guidance during emergency public health threats, delivered and hosted online English and French ICH -GCP training modules, assisted in equipment placements at clinical sites including I-Stat, Bloodmobiles, and engaged local stakeholders through communication, advocacy and community engagement efforts to create a research-friendly environment and sound achievement of R&D efforts during emergency disease outbreaks.
Dr. Amos Ndhere, Chief Medical Officer, ACE Research, LLC is available to discuss vaccine development and the challenges of safely delivering clinical trials in Sub-Saharan Africa in the rapidly evolving COVID-19 environment.
About ACE Research
ACE Research is an African niche full-service CRO specializing in early and late phase clinical trial services and solutions for the vaccine, drug and device development for pharmaceutical, global CRO, government and not-for-profit organizations. With headquarters in Kisumu, Kenya and regional legal registrations and offices in The Democratic Republic of Congo, Sierra Leone, and the U.S, the company operates in 34 countries in Sub-Saharan Africa.
For more information, please visit https://aceresearchafrica.com/
To learn more about COVID-19 clinical trials in Africa, please contact
Dr. Amos Ndhere, Chief Medical Officer
The White Court Apartments
P.O. Box 3964 – 40100
T: (919) 916-8145
E: [email protected]